Hepaseal Tablet is a hepatoprotective formulation combining L-Ornithine L-Aspartate (250 mg) and Silymarin (140 mg), designed to support liver function and promote hepatic detoxification. L-Ornithine L-Aspartate facilitates ammonia detoxification by enhancing the urea cycle, thereby reducing elevated blood ammonia levels commonly observed in hepatic encephalopathy and chronic liver diseases. Silymarin, a flavonoid complex extracted from Silybum marianum, exhibits potent antioxidant, anti-inflammatory, and membrane-stabilizing properties, which contribute to hepatocyte regeneration and protection against oxidative stress-induced liver injury. The synergistic action of these active ingredients aids in improving liver enzyme profiles, alleviating symptoms of liver dysfunction, and enhancing overall liver health. Hepaseal Tablet is indicated for the management of various hepatic disorders, including chronic hepatitis, cirrhosis, fatty liver disease, and toxin-induced liver damage. It is generally well tolerated, with a favorable safety profile when administered as per recommended dosages. Clinical use should be guided by a healthcare professional, considering individual patient conditions and potential drug interactions. Regular monitoring of liver function tests is advised during prolonged therapy to assess therapeutic efficacy and safety. Hepaseal Tablet serves as an adjunctive treatment aimed at restoring hepatic integrity and improving patient quality of life in liver-related ailments.